RxDoctor Payments Data

Elina Kaganovsky

Internal Medicine · Brooklyn, NYNPI 1205867140

Payments from drug & device makers

$2,571in general payments, 2019–2025

Across 140 payments — averaging $18.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$373
  • Ironwood Pharmaceuticals, Inc$323
  • GSK$320
  • AbbVie$311
  • Amarin Pharma, Inc.$270
  • E.r. Squibb & Sons, L.L.C.$192
  • plus $783 from 13 others

What the payments were for

  • Food & beverage$2,571100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,571 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$376,493
Medicare patients
110
Services billed
12,911

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban118$129,982
ZenpepLipase/Protease/Amylase27$109,482
LinzessLinaclotide109$87,743
CreonLipase/Protease/Amylase24$53,627
VascepaIcosapent Ethyl63$35,379
Dexlansoprazole DrDexlansoprazole81$25,926
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$24,327
MyrbetriqMirabegron37$20,141
JardianceEmpagliflozin11$16,615
JanuviaSitagliptin Phosphate19$15,612
XareltoRivaroxaban16$14,282
JanumetSitagliptin Phos/Metformin Hcl13$13,779
OzempicSemaglutide15$13,457
Breo ElliptaFluticasone/Vilanterol28$12,976
Icosapent Ethyl52$12,416

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon, Synthroid$311$144,268157 claims
PfizerEliquis$81$129,982118 claims
GSKTrelegy Ellipta, Breo Ellipta$320$37,30356 claims
Novo NordiskOzempic$41$13,45715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →